Evidence map›Paper›PMID 30863950›Full record

ArticleClinical rheumatology2019

The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.

Shanshan Li, Yongpeng Ge, Hanbo Yang, Tao Wang, Xiaoxiao Zheng, Qinglin Peng, Xin Lu, Guochun Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Dermatomyositis autoantibodies: how can we maximize utility?Annals of translational medicine · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shanshan LiDepartment of Rheumatology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, China.
Yongpeng GeDepartment of Rheumatology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, China.
Hanbo YangDepartment of Rheumatology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, China.
Tao WangDepartment of Rheumatology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, China.
Xiaoxiao ZhengDepartment of Rheumatology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, China.
Qinglin PengDepartment of Rheumatology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, China.
Xin LuDepartment of Rheumatology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, China.
Guochun WangDepartment of Rheumatology, China-Japan Friendship Hospital, No. 2 Yinghua East Street, Chaoyang District, Beijing, China. guochunwang@hotmail.com.
China-Japan Friendship Hospital · CN

Funding

Capital Foundation of Medical Development 2016-2-4063National Natural Science Foundation of China 81571603Science and Technology Commission Foundation of Beijing Z171100001017208
6 · The paper itself

Abstract

objectivesThe aim of this study is to analyze the prevalence of myositis-specific autoantibodies (MSAs) and to elucidate their associations with clinical features in Chinese patients with polymyositis (PM) and dermatomyositis (DM).

methodsTwelve subsets of MSAs including anti-Mi-2, anti-TIF1-γ, anti-MDA5, anti-NXP2, anti-SAE1, anti-SRP, anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, and anti-HMGCR antibodies were tested. Four hundred and ninety-seven PM/DM patients were enrolled. Clinical features and laboratory data were collected. The frequency of MSAs and the correlations with clinical phenotypes were calculated by SPSS 21.0.

resultsMSAs were present in 65.4% in PM/DM patients. Anti-TIF1-γ (14.3%), anti-MDA5 (12.5%), and anti-Jo-1 (10.1%) were the three commonest MSAs. Anti-SAE1 (OR 14.877, 95% CI 1.427-155.074), anti-SRP (OR 4.339, 95% CI 1.529-12.312) and anti-TIF1-γ (OR 2.790, 95% CI 1.578-4.935) were associated with dysphagia. In contrast, anti-MDA5 (OR 0.356, 95% CI 0.148-0.856) might decrease the frequency of this manifestation. Interstitial lung disease (ILD) was observed more frequently in patients carrying anti-EJ (OR 14.202, 95% CI 1.696-118.902), anti-Jo-1 (OR 11.111, 95% CI 3.306-37.335), and anti-MDA5 (OR 3.109, 95% CI 1.578-6.128). On the contrary, anti-Mi-2 (OR 0.180, 95% CI 0.055-0.589), anti-TIF1-γ (OR 0.163, 95% CI 0.080-0.333), and anti-HMGCR (OR 0.058, 95% CI 0.007-0.451) were protective factors against developing ILD. Anti-TIF1-γ was an independent risk factor for cancer-associated myositis (OR 4.237, 95% CI 1.712-10.487).

conclusionsPM/DM patients had high frequencies of MSAs. Several MSAs were independent factors in determining unique clinical phenotypes.

Indexed as

AdultAutoantibodiesAutoantigensChinaDermatomyositisFemaleHumansHydroxymethylglutaryl CoA ReductasesInflammationLung Diseases, InterstitialMaleMiddle AgedMuscular DiseasesMyositisPhenotypePolymyositisAutoantibodiesAutoantigensHMGCR protein, humanHydroxymethylglutaryl CoA ReductasesMi-2 antibodiesDermatomyositisExtramuscular featureMyositis-specific autoantibodyPolymyositis

Identifiers

PMID30863950
OpenAlexW2922272744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.